Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Risperidone vs. Paroxetine for Panic Attacks

This study has been terminated.
Information provided by (Responsible Party):
Beth Israel Medical Center Identifier:
First received: September 13, 2005
Last updated: October 19, 2012
Last verified: October 2012
We are comparing the efficacy of Risperidone versus Paroxetine in the treatment of panic symptoms. The study hypothesis is that Risperidone will be a superior medicine for treating panic.

Condition Intervention Phase
Major Depressive Disorder With Panic Attacks
Panic Disorder
Drug: Risperidone
Drug: Paroxetine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks

Resource links provided by NLM:

Further study details as provided by Beth Israel Medical Center:

Estimated Enrollment: 90
Study Start Date: January 2003
Study Completion Date: July 2005
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, ages 21-55.
  • Ability to sign an informed consent
  • Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
  • HAM-A score >17

Exclusion Criteria:

  • Alcohol or substance abuse within the last 6 months
  • Current diagnosis of Obsessive-Compulsive Disorder
  • Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
  • Use of antipsychotic medications over the two months preceding enrollment in the study
  • Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
  • Previous adverse reaction to risperidone or paroxetine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00206765

United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
Beth Israel Medical Center
Principal Investigator: Igor Galynker, MD, PhD Beth Israel Medical Center
  More Information

Responsible Party: Beth Israel Medical Center Identifier: NCT00206765     History of Changes
Other Study ID Numbers: 082-02 
Study First Received: September 13, 2005
Last Updated: October 19, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Beth Israel Medical Center:

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Panic Disorder
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Anxiety Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Antidepressive Agents, Second-Generation
Antidepressive Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on October 25, 2016